Cytogen Inc
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained wit… Read more
Cytogen Inc (217330) - Net Assets
Latest net assets as of September 2025: ₩41.66 Billion KRW
Based on the latest financial reports, Cytogen Inc (217330) has net assets worth ₩41.66 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩67.68 Billion) and total liabilities (₩26.02 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩41.66 Billion |
| % of Total Assets | 61.56% |
| Annual Growth Rate | 58.52% |
| 5-Year Change | 164.95% |
| 10-Year Change | 1725.37% |
| Growth Volatility | 358.82 |
Cytogen Inc - Net Assets Trend (2014–2024)
This chart illustrates how Cytogen Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cytogen Inc (2014–2024)
The table below shows the annual net assets of Cytogen Inc from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩48.58 Billion | -8.94% |
| 2023-12-31 | ₩53.36 Billion | +843.31% |
| 2022-12-31 | ₩5.66 Billion | -75.42% |
| 2021-12-31 | ₩23.01 Billion | +25.48% |
| 2020-12-31 | ₩18.34 Billion | +2.33% |
| 2019-12-31 | ₩17.92 Billion | -18.70% |
| 2018-12-31 | ₩22.04 Billion | +365.76% |
| 2017-12-31 | ₩4.73 Billion | +895.21% |
| 2016-12-31 | ₩475.51 Million | -82.13% |
| 2015-12-31 | ₩2.66 Billion | +449.23% |
| 2014-12-31 | ₩484.59 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cytogen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8273587282000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩11.56 Billion | 23.80% |
| Other Components | ₩122.21 Billion | 251.54% |
| Total Equity | ₩48.58 Billion | 100.00% |
Cytogen Inc Competitors by Market Cap
The table below lists competitors of Cytogen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GEA Grenobl. Elect.
PA:GEA
|
$27.03 Million |
|
Development Advance Solution Co Ltd
KO:058730
|
$27.03 Million |
|
International Gas Product Shipping JSC
VN:GSP
|
$27.03 Million |
|
HYUNDAI BIOLAND Co.Ltd
KQ:052260
|
$27.04 Million |
|
Datagate Bilgisayar Malzemeleri Ticaret AS
IS:DGATE
|
$27.01 Million |
|
Singha Estate Public Company Limited
BK:S
|
$27.01 Million |
|
ICBC Turkey Bank AS
IS:ICBCT
|
$27.00 Million |
|
DAEMO Engineering Co. Ltd
KQ:317850
|
$27.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cytogen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 53,355,392,640 to 48,583,191,260, a change of -4,772,201,380 (-8.9%).
- Net loss of 17,116,994,930 reduced equity.
- Share repurchases of 6,500,000,450 reduced equity.
- New share issuances of 6,500,000,440 increased equity.
- Other factors increased equity by 12,344,793,560.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-17.12 Billion | -35.23% |
| Share Repurchases | ₩6.50 Billion | -13.38% |
| Share Issuances | ₩6.50 Billion | +13.38% |
| Other Changes | ₩12.34 Billion | +25.41% |
| Total Change | ₩- | -8.94% |
Book Value vs Market Value Analysis
This analysis compares Cytogen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.22x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 37.99x to 2.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩123.32 | ₩4685.00 | x |
| 2017-12-31 | ₩1076.05 | ₩4685.00 | x |
| 2018-12-31 | ₩3912.31 | ₩4685.00 | x |
| 2019-12-31 | ₩3180.77 | ₩4685.00 | x |
| 2020-12-31 | ₩3254.77 | ₩4685.00 | x |
| 2021-12-31 | ₩1314.62 | ₩4685.00 | x |
| 2022-12-31 | ₩317.61 | ₩4685.00 | x |
| 2023-12-31 | ₩2408.36 | ₩4685.00 | x |
| 2024-12-31 | ₩2105.94 | ₩4685.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cytogen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -156.88%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.49x
- Recent ROE (-35.23%) is above the historical average (-130.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -283.35% | -381.75% | 0.18x | 4.24x | ₩-1.42 Billion |
| 2015 | -143.13% | -777.99% | 0.12x | 1.60x | ₩-4.08 Billion |
| 2016 | -451.97% | -252.89% | 0.17x | 10.64x | ₩-2.20 Billion |
| 2017 | -55.37% | -1272.69% | 0.04x | 1.20x | ₩-3.09 Billion |
| 2018 | -11.79% | -212.09% | 0.05x | 1.03x | ₩-4.80 Billion |
| 2019 | -23.11% | -518.30% | 0.04x | 1.10x | ₩-5.93 Billion |
| 2020 | -26.66% | -760.70% | 0.02x | 1.54x | ₩-6.72 Billion |
| 2021 | -47.25% | -3125.13% | 0.01x | 2.41x | ₩-13.17 Billion |
| 2022 | -331.87% | -2467.37% | 0.02x | 7.29x | ₩-19.34 Billion |
| 2023 | -29.56% | -495.22% | 0.04x | 1.40x | ₩-21.11 Billion |
| 2024 | -35.23% | -156.88% | 0.15x | 1.49x | ₩-21.98 Billion |
Industry Comparison
This section compares Cytogen Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $84,307,728,831
- Average return on equity (ROE) among peers: -11.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cytogen Inc (217330) | ₩41.66 Billion | -283.35% | 0.62x | $27.02 Million |
| NSN Co. Ltd (031860) | $102.59 Billion | 0.00% | 0.91x | $4.54 Million |
| JOONGANG DNM Co.Ltd (051980) | $24.46 Billion | -32.51% | 0.43x | $77.93 Million |
| GeneMatrix Inc (109820) | $32.32 Billion | -3.06% | 0.22x | $21.53 Million |
| Genoray Co. Ltd (122310) | $11.35 Billion | 17.59% | 1.51x | $24.43 Million |
| Green Cross Lab Cell Corporation (144510) | $457.79 Billion | -16.14% | 0.26x | $147.96 Million |
| Optipharm.CO.LTD (153710) | $25.14 Billion | -9.69% | 0.56x | $30.10 Million |
| U2Bio Co., Ltd. (221800) | $33.84 Billion | 38.88% | 0.51x | $84.13 Million |
| Gencurix Inc (229000) | $8.20 Billion | -110.48% | 0.13x | $21.11 Million |
| P&K Skin Research Center Co. Ltd (347740) | $63.07 Billion | 11.56% | 0.06x | $15.93 Million |